PHARMA JAPAN welcomes JETRO New York’s Shunsuke Tani as a guest columnist. In occasional contributions, Tani will share his perspectives on US pharmaceutical policy, industry developments, and life in America, drawing on his firsthand experience in the US.---Hello from New…
BUSINESS
Zolgensma’s Japan Launch Delayed into 2020 as Sakigake Review Drags On, MHLW Still Eager to Make Decision by Year-End
The Japan debut of Novartis’ spinal muscular atrophy (SMA) gene therapy Zolgensma is expected to be delayed into next year as regulators have yet to wrap up its review nearly a year after its filing despite its sakigake tag. Although…
To read the full story
Related Article
- Novartis’ Flawed and Delayed Inquiry Responses in Zolgensma Review “Extremely Unusual”: PMDA Report
April 16, 2020
- Zolgensma Up for Japan Advisory Panel Meeting on Feb. 26, Listing Expected as Early as May
February 17, 2020
- Zolgensma Not on Roster for Nov. 13 MHLW Panel Review
November 7, 2019
- Novartis’ SMA Gene Therapy Filed in Japan on Nov. 1 after US, EU; What Will Happen to Sakigake Status?
November 13, 2018
- AVXS-101 Is Game Changer for SMA Treatment: Novartis Neuroscience Chief
October 24, 2018
BUSINESS
- Wholesalers See NHI-Market Price Gap Falling Below 4.8% to New Record Low
October 26, 2026
- Vyepti Could Expand Migraine Treatment Options: Japanese Expert
October 26, 2026
- Zeria to Buy German Asacol Manufacturing Partner
October 26, 2026
- Otsuka’s IgAN Drug Voyxact Cuts Kidney Event Risk by 97%
October 26, 2026
- NEC’s Neoantigen Therapy Shows Immunogenicity in Early TNBC Trial
October 26, 2026
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…